Relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine in chronic kidney disease: a secondary analysis of the DANFLU-1 trial

K Bartholdy,N D Johansen,K H Janstrup,D Modin,J Nealon,S Samson,C Salamand,M M Loiacono,A M R Jensen,N E Landler,B L Claggett,S D Solomon,G H Gislason,L Koeber,T Biering-Soerensen
DOI: https://doi.org/10.1093/eurheartj/ehae666.3272
IF: 39.3
2024-10-30
European Heart Journal
Abstract:Background Morbidity and mortality from influenza and cardiovascular disease occur frequently in persons with chronic kidney disease (CKD). Limited data exist on the effectiveness of high-dose influenza vaccination in persons with CKD. Purpose To assess the relative effectiveness of high-dose quadrivalent influenza vaccine (QIV-HD) vs. standard-dose quadrivalent influenza vaccine (QIV-SD) against clinical outcomes in persons with CKD. Methods In this secondary analysis of the DANFLU-1 trial, a randomized controlled feasibility trial to assess QIV-HD vs QIV-SD in the 2021-2022 influenza season, CKD was defined according to current KDIGO guidelines using data from laboratory registries and hospital diagnoses <6 years prior to vaccination. Prespecified outcomes in DANFLU-1 included time-to-first event of hospitalization for influenza or pneumonia, cardiovascular, cardiorespiratory, respiratory, and COVID-19 hospitalizations, all-cause hospitalization, and all-cause mortality. Outcomes were analyzed as both time-to-first and recurrent events. Cox proportional hazards regression was used to determine hazards ratios (HR) assessing the effectiveness of QIV-HD compared with QIV-SD for all time to first event analysis in CKD and non-CKD participants. Negative binomial regression was used to compute incidence rate ratios (IRR) for recurrent event analysis of all prespecified clinical outcomes. Interaction terms between CKD status and all outcomes were included to test for effect modification. Results Of 12,473 DANFLU-1 participants randomized to QIV-HD or QIV-SD, 1,878 had CKD. Among those with CKD, 14 were hospitalized with influenza or pneumonia. QIV-HD was associated with a lower incidence of hospitalization against influenza or pneumonia compared with QIV-SD (Figure 1: HR 0.25 [0.07-0.91], p 0.035). No other statistically significant differences were found in the time to first event analysis (Figure 1). In recurrent event analysis among persons with CKD, QIV-HD was associated with reduced risk of hospitalization for pneumonia (IRR 0.17 [0.04 – 0.70]; p 0.014), cardiorespiratory hospitalization (IRR 0.56 [0.32 - 0.99]; p 0.046, and all-cause hospitalization (IRR 0.74 [0.56 – 0.98]; p 0.038) (Figure 2). The presence of CKD at baseline did not modify the effect of QIV-HD compared with QIV-SD for any of the outcomes assessed. Conclusion In this secondary analysis of a large-scale pragmatic randomized trial, QIV-HD was associated with reductions in a broad range of clinical outcomes in persons with and without CKD. The potential superior effectiveness of QIV-HD compared to QIV-SD may therefore also apply to persons with CKD.
cardiac & cardiovascular systems
What problem does this paper attempt to address?